

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
702-010411

SERIAL NO.
09/806,178

INFORMATION DISCLOSURE STATEMENT
STATEMENT BY APPLICANT

APPLICANT

Nobuo NAGAI et al.

FILING DATE
June 18, 2001

GROUP 1647
ART UNIT Not Yet Assigned

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
GW	AL 9 8 1 2 3 2 9	03/1998	WIPO			
GW	AM 0 6 3 1 7 8 6	04/1995	European Patent Office			
	AN					
	AO					
	AP					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

GW	AQ	Butte, A. et al., "Alpha2-antiplasmin causes thrombi to resist fibrinolysis induced by tissue plasminogen activator in experimental pulmonary embolism," <i>Circulation</i> 95(7): 1886-1891(1997)
↓	AR	Reed, G., "Functional characterization of monoclonal antibody inhibitors of alpha2-antiplasmin that accelerate fibrinolysis in different animal plasmas," <i>Hybridoma</i> 16(3): 281-286 (1997)
GW	AS	Nagai, N., et al. "Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice," <i>Circulation</i> 99(18): 2440-2444 (1999)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
702-010411SERIAL NO.
09/806,178INFORMATION DISCLOSURE STATEMENT
STATEMENT BY APPLICANT

APPLICANT

Nobuo NAGAI et al.

FILING DATE
June 18, 2001GROUP 1647
ART UNIT ~~Not Yet Assigned~~

Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AL							
	AM							
	AN							
	AO							
	AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

cn	AT	—	Collen, D. "Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent," <i>Nature Medicine</i> 4(3): 279-284 (1998)
↓	AU	—	Coyle, J.T. et al. "Oxidative stress, glutamate and neurodegenerative disorders," <i>Science</i> 262: 689-695 (1993)
gn	AV	—	Coyle, J.T. et al. "In situ injection of kainic acid: a new method for selectively lesioning neuronal cell bodies while sparing axons of passage," <i>J Comp Neurol</i> 180: 301-323 (1978)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

MAR 31 2003

TECH CENTER 1600/2900 Sheet 3 of 12

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
702-010411SERIAL NO.
09/806,178INFORMATION DISCLOSURE STATEMENT
STATEMENT BY APPLICANT

APPLICANT

Nobuo NAGAI et al.

FILING DATE
June 18, 2001GROUP 1647
ART UNIT Not Yet Assigned

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO
AL					
AM					
AN					
AO					
AP					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AW	—	Tsirka, S.E. et al. "Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator," <i>Nature</i> 377: 340-344 (1995)
AX	—	Tsirka, S.E. et al. "An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus," <i>J Neurosci</i> 17(2): 543-552 (1997)
AY	—	Tsirka, S.E. et al. "Neuronal cell death and t-PA," <i>Nature</i> 384: 123-124 (1996)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
702-010411SERIAL NO.
09/806,178INFORMATION DISCLOSURE STATEMENT
STATEMENT BY APPLICANT

APPLICANT

Nobuo NAGAI et al.

FILING DATE
June 18, 2001GROUP **K07**
ART UNIT ~~Not Yet Assigned~~

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AL							
	AM							
	AN							
	AO							
	AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CA	AZ	—	Chen, Z.L. et al. "Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin," <i>Cell</i> 91: 917-925 (1997)
CA	BA	—	Wang, Y.F. et al. "Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPa-deficient mice," <i>Nature Medicine</i> 4(2): 228-231 (1998)
CA	BB	—	Nagai, N. et al. "Comparative effects of tissue-type plasminogen activator, streptokinase, and staphylokinase on cerebral ischemic infarction and pulmonary clot lysis in hamster models," <i>Circulation</i> 100: 2541-2546 (1999)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
702-010411

SERIAL NO.
09/806,178

INFORMATION DISCLOSURE STATEMENT
STATEMENT BY APPLICANT

APPLICANT

Nobuo NAGAI et al.

FILING DATE
June 18, 2001

GROUP **1647**
ART UNIT ~~Not Yet Assigned~~

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO
AL					
AM					
AN					
AO					
AP					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BC	—	The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group "Tissue plasminogen activator for acute ischemic stroke," <i>N Engl J Med</i> 333(24): 1581-1587 (1995)
BD	—	Hacke, W. et al. for the ECASS Study Group "Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS)," <i>J Am Med Ass</i> 274(13): 1017-1025 (1995)
BE	—	Collen, D. et al. "Turnover of antiplasmin, the fast-acting plasmin inhibitor of plasma," <i>Blood</i> 53(2): 313-324 (1979)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

MAR 31 2003

Sheet 6 of 12

TECH CENTER 1600/2900

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
702-010411SERIAL NO.
09/806,178INFORMATION DISCLOSURE STATEMENT
STATEMENT BY APPLICANT

APPLICANT

Nobuo NAGAI et al.

FILING DATE
June 18, 2001GROUP 1647
ART UNIT ~~Not Yet Assigned~~

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AL							
	AM							
	AN							
	AO							
	AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CJN	BF	—	Carmeliet, P. et al. "Physiological consequences of loss of plasminogen activator gene function in mice," <i>Nature</i> 368: 419-424 (1994)
CJN	BG	—	Carmeliet, P. et al. "Plasminogen activator inhibitor-1 gene-deficient mice: I. Generalization by homologous recombination and characterization," <i>J Clin Invest</i> 92: 2746-2755 (1993)
CJN	BH	—	Carmeliet, P. et al. "Plasminogen activator inhibitor-1 gene deficient mice: II. Effects on hemostasis, thrombosis, and thrombolysis," <i>J Clin Invest</i> 92:2756-2760 (1993)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

MAR 24 2003

Sheet 7 of 12

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
702-010411SERIAL NO.
09/806,178INFORMATION DISCLOSURE STATEMENT
STATEMENT BY APPLICANT

APPLICANT

Nobuo NAGAI et al.

FILING DATE
June 18, 2001GROUP **1647**
ART UNIT ~~Not Yet Assigned~~

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AL							
	AM							
	AN							
	AO							
	AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CSN	BI	—	Ploplis, V.A. et al. "Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice," <i>Circulation</i> 92(9): 2585-2593 (1995)
CSN	BJ	—	Lijnen, H.R. et al. "Alpha2-antiplasmin gene-deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding," <i>Blood</i> 93(7): 2274-2281 (1999)
CSN	BK	—	Dewerchin, M. et al. "Generation and characterization of urokinase receptor-deficient mice," <i>J Clin Invest</i> 97(3): 870-878 (1996)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

MAR 24 2003

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
702-010411

SERIAL NO.
09/806,178

INFORMATION DISCLOSURE STATEMENT
STATEMENT BY APPLICANT

APPLICANT

Nobuo NAGAI et al.

(Use several sheets if necessary)

FILING DATE
June 18, 2001

GROUP **1647**
ART UNIT ~~Not Yet Assigned~~

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
AL							
AM							
AN							
AO							
AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CJW	BL	—	Lijnen, H.R. et al. "Amino-acid sequence of human Alpha2-antiplasmin," <i>Eur J Biochem</i> 166: 565-574 (1987)
QJW	BM	—	McGrory, W.J. et al. "A simple technique for the rescue of early region 1 mutations into infectious human adenovirus type 5," <i>Virology</i> 163: 614-617 (1988)
QJW	BN	—	Gomez-Foix, A.M. et al. "Adenovirus-mediated transfer of the muscle glycogen phosphorylase gene into hepatocytes confers altered regulation of glycogen metabolism," <i>J Biol Chem</i> 267(35): 25129-25134 (1992)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

MAR 24 2003

MAR 31 2003

TECH CENTER 1600/2900 9 of 12

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
702-010411SERIAL NO.
09/806,178INFORMATION DISCLOSURE STATEMENT
STATEMENT BY APPLICANT

APPLICANT

Nobuo NAGAI et al.

(Use several sheets if necessary)

FILING DATE
June 18, 2001GROUP **1647**
ART UNIT ~~Not Yet Assigned~~

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AL							
	AM							
	AN							
	AO							
	AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

GN	BO	—	Graham, F.L. et al. "Characteristics of a human cell line transformed by DNA from human adenovirus type 5," <i>J Gen Virol</i> 36: 59-72 (1977)
GN	BP	—	Gerard, R.D., Meidel, R.S. "Adenovirus vectors. In: Hames, B.D., Glover, D. (eds.) DNA Cloning 4 - A practical approach: mammalian systems," Oxford, UK, pp. 285-306 (1995)
GN	BQ	—	Alcorn, J.L. et al. "Genomic elements involved in transcriptional regulation of the rabbit surfactant protein-A gene," <i>Mol Endocrinol</i> 7(8): 1072-1085 (1993)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

MAR 24 2003

Sheet 10 of 12

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
702-010411SERIAL NO.
09/806,178INFORMATION DISCLOSURE STATEMENT
STATEMENT BY APPLICANT

APPLICANT

Nobuo NAGAI et al.

(Use several sheets if necessary)

FILING DATE
June 18, 2001GROUP **1647**
ART UNIT ~~Not Yet Assigned~~

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AL							
	AM							
	AN							
	AO							
	AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CPW	BR	—	Kopfler, W. P. et al. "Adenovirus-mediated transfer of a gene encoding human apolipoprotein A-I into normal mice increases circulating high-density lipoprotein cholesterol," <i>Circulation</i> 90(3): 1319-1327 (1994)
CPW	BS	—	Carmeliet, P. et al. "Adenovirus-mediated transfer of tissue-type plasminogen activator augments thrombolysis in tissue-type plasminogen activator-deficient and plasminogen activator inhibitor-1-overexpressing mice," <i>Blood</i> 90(4): 1527-1534 (1997)
CPW	BT	—	Carmeliet, P. et al. "Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation," <i>Circulation</i> 96(9): 3180-3191 (1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

MAR 3 1 2003

MAR 2 4 2003

MAR 3 1 2003

TECH CENTER 1600/2900 11 of 12

FORM PTO-149, U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
702-010411SERIAL NO.
09/806,178INFORMATION DISCLOSURE STATEMENT
STATEMENT BY APPLICANT

APPLICANT

Nobuo NAGAI et al.

(Use several sheets if necessary)

FILING DATE
June 18, 2001GROUP 1647
ART UNIT Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AL							
	AM							
	AN							
	AO							
	AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CW	BU	—	Deutsch, D.G. et al. "Plasminogen purification from human plasma by affinity chromatography," <i>Science</i> 170: 1095-1096 (1970)
CW	BV	—	Edy, J. et al. "Inhibition of plasmin by normal and antiplasmin-depleted human plasma," <i>Thromb. Res.</i> 8: 513-518 (1976)
CW	BW	—	Welsh, F.A. et al. "Effect of lactacidosis on pyridine nucleotide stability during ischemia in mouse brain," <i>J Neurochem</i> 49(3): 846-851 (1987)

EXAMINER

DATE CONSIDERED

4/21/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
702-010411SERIAL NO.
09/806,178INFORMATION DISCLOSURE STATEMENT
STATEMENT BY APPLICANT

APPLICANT

Nobuo NAGAI et al.

FILING DATE
June 18, 2001GROUP 1647
ART UNIT Not Yet Assigned

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
AL							
AM							
AN							
AO							
AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CW	BX	—	Bederson, J.B. et al. "Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination," <i>Stroke</i> 17(3): 472-476 (1986)
CW	BY	—	Bederson, J.B. et al. "Evaluation of 2, 3, 5-triphenyltetrazolium chloride as a stain for detection and quantification of Experimental cerebral infarction in rats," <i>Stroke</i> 17(6): 1304-1308 (1986)
	BZ		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.